The undersigned certifies that this correspondence is being sent via

First Class Mail in an envelope addressed to:

Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,

this 9th day of

s i Timoreda, Ph.D.

MAR 12 2007

Docket No. ORT1590USCIP

1617

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Breitenbucher et al.

Serial No.: 10/075,673 Art Unit:

February 13, 2002 Examiner: Shengjun Wang Filed:

For: Method for Treating Allergies Using Substituted Pyrazoles

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SIXTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

03/13/2007 HLE333 00000021 100750 10075673

180.00 DA 01 FC:1806

	\cdot	
,	☐ In accordance with §1.97(b), since this Information	
	Disclosure Statement is being filed either within three months of	
	the filing date of the above-identified national application	
	(other than a continued prosecution application under §1.53(d)),	
	within three months of the date of entry into the national stage	
	of the above identified application as set forth in §1.491, or	
	before the mailing date of a first Office Action on the merits of	
	the above-identified application, or before the mailing date of a	
	first Office Action after the filing of a request for continued	
	examination under §1.114, no additional fee is required.	
	In accordance with §1.129(a), this Information	
	Disclosure Statement is being filed in connection with _ the	
	first or second After Final Submission, therefore:	
	Statement in Accordance with §1.97(e) (attached);	
	or .	
	Please charge Deposit Account No. 10-	
	0750/ / the fee of \$180.00 as set forth in	
	§1.17(p).	
	☐ In accordance with §1.97(c), this Information	
	Disclosure Statement is being filed after the period set forth in	
	§1.97(b) above but before the mailing date of either a Final	
	Action under §1.113 or a Notice of Allowance under §1.311, or an	
•	action that otherwise closes prosecution and that it is	
	accompanied by one of:	
	Statement in Accordance with §1.97(e) (attached);	
	or	
	☐ Please charge Deposit Account No. 10-	
	0750/ORT1590/JJT the fee of \$180.00 as set forth in	
	§1.17(p).	
	21.11/61.	
	- 2 -	

,	
•	
	In accordance with $\S1.97(d)$, this Information Disclosure Statement is being filed after the mailing date of either a Final Action under $\S1.113$ or a Notice of Allowance under $\S1.311$ but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with $\S1.97(e)$ as set forth below and the fee of $\S180.00$ as set forth in $\S1.17(p)$.
•	Copies of each of the references listed on the attached
	Form PTO-1449 are enclosed herewith.
	Copies of references listed on the attached Form PTO- 1449 are enclosed herewith EXCEPT THAT:
	In view of the voluminous nature of references, and the likelihood that these references are available to the Examiner, copies are not enclosed herewith. Copies of references that have been made of record in U.S. Application serial number, filed, are not supplied herewith.
	If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
•	□ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). □ There are no listed references which are not in the English language.
	Concerning references which are not in the English language, the following comments are made:

Attached are copies of search report(s) from	
corresponding patent application(s).	
Attached are the following non-published pending pater	ıt
applications which may be deemed relevant, which are listed on t	he
attached Submission Under MPEP 609 D.	

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT1590/JJT. This document is being provided in duplicate.

Respect 11y submitted,

regus Vuanos i Timoneda Reg. No. 43,332

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (858) 320-3549 DATED: March 9, 2007



applicant.

/گ			Sheet1_	of1_
			- In	
*QRM#250*1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ORT1590USCIP	SERIAL NO. 10/075,673	
	MATION DISCLOSURE	APPLICANT Breitenbucher et al.		
(Use several sheets if necessary)		FILING DATE February 13, 2002	GROUP ART UNIT 1617	
	US PA	TENT DOCUMENTS		
EXAMINER INITIAL		NUMBER, INVENTORS, DATE		FILING DATE IF APPROPRIATE
	US 3,994,890 Fujimura et al. 11-3	30-1976		
	FOREIGN	PATENT DOCUMENTS		
EXAMINER INITIAL		NUMBER, APPLICANT, DATE		TRANSLATION (IF APPLICABLE)
	ОТН	ER DOCUMENTS		
EXAMINER INITIAL	нтиа	IOR, TITLE, DATE, PERTINEN	T PAGES, etc.	_
	REISE, R.J. et al. Essential Role for Processing and Peptide Loading.			nt Chain
EXAMINER		DATE CONSIDERED		